Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents. / Byonanebye, Dathan M.; Polizzotto, Mark N.; Begovac, Josip; Grabmeier-Pfistershammer, Katharina; Abela, Irene; Castagna, Antonella; de Wit, Stéphane; Mussini, Cristina; Vehreschild, Jörg J.; d'Arminio Monforte, Antonella; Wit, Ferdinand W.N.M.; Pradier, Christian; Chkhartishvili, Nikoloz; Sönnerborg, Anders; Hoy, Jennifer; Lundgren, Jens; Neesgaard, Bastian; Bansi-Matharu, Loveleen; Greenberg, Lauren; Llibre, Josep M.; Vannappagari, Vani; Gallant, Joel; Necsoi, Coca; Cichon, Piotr; Reiss, Peter; Aho, Inka; Tsertsvadze, Tengiz; Mennozzi, Marianna; Rauch, Andri; Muccini, Camilla; Law, Matthew; Mocroft, Amanda; Ryom, Lene; Petoumenos, Kathy; Hillebregt, M.; Rose, N.; Zangerle, R.; Appoyer, H.; Delforge, M.; Wandeler, Gilles; Stephan, C.; Bucht, M.; Chokoshvili, O.; Rodano, A.; Tavelli, A.; Fanti, I.; Borghi, V.; Fontas, E.; Dollet, K.; Caissotti, C.; The Respond Study Group.
In: AIDS, Vol. 35, No. 6, 2021, p. 869-882.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents
AU - Byonanebye, Dathan M.
AU - Polizzotto, Mark N.
AU - Begovac, Josip
AU - Grabmeier-Pfistershammer, Katharina
AU - Abela, Irene
AU - Castagna, Antonella
AU - de Wit, Stéphane
AU - Mussini, Cristina
AU - Vehreschild, Jörg J.
AU - d'Arminio Monforte, Antonella
AU - Wit, Ferdinand W.N.M.
AU - Pradier, Christian
AU - Chkhartishvili, Nikoloz
AU - Sönnerborg, Anders
AU - Hoy, Jennifer
AU - Lundgren, Jens
AU - Neesgaard, Bastian
AU - Bansi-Matharu, Loveleen
AU - Greenberg, Lauren
AU - Llibre, Josep M.
AU - Vannappagari, Vani
AU - Gallant, Joel
AU - Necsoi, Coca
AU - Cichon, Piotr
AU - Reiss, Peter
AU - Aho, Inka
AU - Tsertsvadze, Tengiz
AU - Mennozzi, Marianna
AU - Rauch, Andri
AU - Muccini, Camilla
AU - Law, Matthew
AU - Mocroft, Amanda
AU - Ryom, Lene
AU - Petoumenos, Kathy
AU - Hillebregt, M.
AU - Rose, N.
AU - Zangerle, R.
AU - Appoyer, H.
AU - Delforge, M.
AU - Wandeler, Gilles
AU - Stephan, C.
AU - Bucht, M.
AU - Chokoshvili, O.
AU - Rodano, A.
AU - Tavelli, A.
AU - Fanti, I.
AU - Borghi, V.
AU - Fontas, E.
AU - Dollet, K.
AU - Caissotti, C.
AU - The Respond Study Group
N1 - Publisher Copyright: Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2021
Y1 - 2021
N2 - Objective: To compare the incidence of dyslipidemia in people with HIV receiving integrase inhibitors (INSTI) versus boosted protease inhibitors (PI/b) and nonnucleoside reverse transcriptase inhibitors (NNRTI) within RESPOND consortium of prospective cohorts. Methods: Participants were eligible if they were at least 18 years, without dyslipidemia and initiated or switched to a three-drug antiretroviral therapy (ART)-regimen consisting of either INSTI, NNRTI, or PI/b for the first time, between 1 January 2012 and 31 December 2018. Dyslipidemia was defined as random total cholesterol more than 240 mg/dl, HDL less than 35 mg/dl, triglyceride more than 200 mg/dl, or initiation of lipid-lowering therapy. Poisson regression was used to determine the adjusted incidence rate ratios. Follow-up was censored after 3 years or upon ART-regimen discontinuation or last lipid measurement or 31 December 2019, whichever occurred first. Results: Overall, 4577 people with HIV were eligible (INSTI = 66.9%, PI/b = 12.5%, and NNRTI = 20.6%), 1938 (42.3%) of whom were ART-naive. During 1.7 (interquartile range, 0.6 - 3.0) median years of follow-up, 1460 participants developed dyslipidemia [incidence rate: 191.6 per 1000 person-years, 95% confidence interval (CI) 182.0 - 201.7]. Participants taking INSTI had a lower incidence of dyslipidemia compared with those on PI/b (adjusted incidence rate ratio 0.71; CI 0.59 - 0.85), but higher rate compared with those on NNRTI (1.35; CI 1.15 - 1.58). Compared with dolutegravir, the incidence of dyslipidemia was higher with elvitegravir/cobicistat (1.20; CI 1.00 - 1.43) and raltegravir (1.24; CI 1.02 - 1.51), but lower with rilpivirine (0.77; CI 0.63 - 0.94). Conclusion: In this large consortium of heterogeneous cohorts, dyslipidemia was less common with INSTI than with PI/b. Compared with dolutegravir, dyslipidemia was more common with elvitegravir/cobicistat and raltegravir, but less common with rilpivirine.
AB - Objective: To compare the incidence of dyslipidemia in people with HIV receiving integrase inhibitors (INSTI) versus boosted protease inhibitors (PI/b) and nonnucleoside reverse transcriptase inhibitors (NNRTI) within RESPOND consortium of prospective cohorts. Methods: Participants were eligible if they were at least 18 years, without dyslipidemia and initiated or switched to a three-drug antiretroviral therapy (ART)-regimen consisting of either INSTI, NNRTI, or PI/b for the first time, between 1 January 2012 and 31 December 2018. Dyslipidemia was defined as random total cholesterol more than 240 mg/dl, HDL less than 35 mg/dl, triglyceride more than 200 mg/dl, or initiation of lipid-lowering therapy. Poisson regression was used to determine the adjusted incidence rate ratios. Follow-up was censored after 3 years or upon ART-regimen discontinuation or last lipid measurement or 31 December 2019, whichever occurred first. Results: Overall, 4577 people with HIV were eligible (INSTI = 66.9%, PI/b = 12.5%, and NNRTI = 20.6%), 1938 (42.3%) of whom were ART-naive. During 1.7 (interquartile range, 0.6 - 3.0) median years of follow-up, 1460 participants developed dyslipidemia [incidence rate: 191.6 per 1000 person-years, 95% confidence interval (CI) 182.0 - 201.7]. Participants taking INSTI had a lower incidence of dyslipidemia compared with those on PI/b (adjusted incidence rate ratio 0.71; CI 0.59 - 0.85), but higher rate compared with those on NNRTI (1.35; CI 1.15 - 1.58). Compared with dolutegravir, the incidence of dyslipidemia was higher with elvitegravir/cobicistat (1.20; CI 1.00 - 1.43) and raltegravir (1.24; CI 1.02 - 1.51), but lower with rilpivirine (0.77; CI 0.63 - 0.94). Conclusion: In this large consortium of heterogeneous cohorts, dyslipidemia was less common with INSTI than with PI/b. Compared with dolutegravir, dyslipidemia was more common with elvitegravir/cobicistat and raltegravir, but less common with rilpivirine.
U2 - 10.1097/QAD.0000000000002811
DO - 10.1097/QAD.0000000000002811
M3 - Journal article
C2 - 33443370
AN - SCOPUS:85104047208
VL - 35
SP - 869
EP - 882
JO - AIDS
JF - AIDS
SN - 1350-2840
IS - 6
ER -
ID: 302096055